The GSEA revealed that the metastasis-related pathways (i.e., angiogenesis, KRAS signaling, epithelial mesenchymal transit, and myogenesis pathways) were enriched in the high-risk group, all of which were well known to play a crucial role in the progression and proliferation of CRC in numerous studies (Cooks et al., 2013; De Simone et al., 2015; Lu et al., 2016). The gene discussed is KRAS; the disease is colorectal carcinoma.